A Randomized, Double-blind, Placebo-controlled Study of the Safety, Pharmacodynamics, Efficacy, and Pharmacokinetics of TIMP-GLIA in Subjects With Well-controlled Celiac Disease Undergoing Oral Gluten Challenge
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 22 Oct 2019
Price : $35 *
At a glance
- Drugs TAK 101 (Primary)
- Indications Coeliac disease
- Focus Pharmacodynamics
- Sponsors Cour Pharmaceutical Development
- 22 Oct 2019 According to a Takeda media release, data was presented today as a late-breaking abstract at UEG Week 2019, Barcelona, Spain.
- 22 Oct 2019 Results presented in a Takeda media release.
- 18 Jun 2019 Planned End Date changed from 1 May 2019 to 1 Jul 2019.